Sangamo Therapeutics (SGMO) Q4 results:
Revenues: $54.9M (+104.9%).
Net Income: $4.6M (+124.6%); EPS: $0.04 (+122.2%); Quick Assets: $385M (-3.9%).
The increase in revenue was primarily attributable
to a $25M and $7.5M milestone payments received from Pfizer and Sanofi,
respectively.
Shares are up 36% premarket.
Previously: Sangamo Therapeutics EPS beats by $0.38, beats on revenue (Feb. 28)
https://seekingalpha.com/news/3546967-sangamo-therapeutics-beats-q4-consensus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.